Figure 1.
Experimental scheme for study of the antileukemic activity of selinexor (KPT-330) in immunodeficient mice engrafted with primary human AML cells. Mouse xenograft models of human primary AML were established for use in therapeutic experiments to assess the efficacy of Selinexor against AML cells isolated from patients with AML-CK1, AML-CK2 and AML-CN (see Table 1). BM, bone marrow.